Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Preferred Stock Liabilities (2020 - 2023)

Historic Preferred Stock Liabilities for Mimedx (MDXG) over the last 4 years, with Q3 2023 value amounting to $92.5 million.

  • Mimedx's Preferred Stock Liabilities changed 0.0% to $92.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $92.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $92.5 million for FY2022, which is 0.0% changed from last year.
  • Per Mimedx's latest filing, its Preferred Stock Liabilities stood at $92.5 million for Q3 2023, which was down 0.0% from $92.5 million recorded in Q2 2023.
  • In the past 5 years, Mimedx's Preferred Stock Liabilities ranged from a high of $92.5 million in Q2 2021 and a low of $91.1 million during Q3 2020
  • Over the past 4 years, Mimedx's median Preferred Stock Liabilities value was $92.5 million (recorded in 2021), while the average stood at $92.3 million.
  • In the last 5 years, Mimedx's Preferred Stock Liabilities skyrocketed by 152.13% in 2021 and then changed by 0.0% in 2022.
  • Quarter analysis of 4 years shows Mimedx's Preferred Stock Liabilities stood at $91.6 million in 2020, then increased by 1.01% to $92.5 million in 2021, then changed by 0.0% to $92.5 million in 2022, then changed by 0.0% to $92.5 million in 2023.
  • Its last three reported values are $92.5 million in Q3 2023, $92.5 million for Q2 2023, and $92.5 million during Q1 2023.